Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR
Meletios Α. Dimopoulos(Korea University), Rubén Niesvizky(Cornell University), David S. Siegel(Hackensack Meridian Health), Heinz Ludwig(Wilhelminen Hospital), Amy Kimball(University of Maryland, Baltimore), Zhao Yang(Amgen (United States)), Ralph V. Boccia(Center for Cancer and Blood Disorders), Khalid Mezzi(Amgen (United States)), Karim Iskander(Amgen (United States)), Darrell White(Dalhousie University)
Cited by 44
Related Papers
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k
Hematological findings and complications of <scp>COVID</scp>‐19
|American Journal of Hematology|2020|1.7k